4 Results

People

  1. Macgregor-Cortelli
    Macgregor-Cortelli
  2. O'connor
    O'connor
  3. Muzzy
    Muzzy
  4. Hamlin
    Hamlin
  5. Moskowitz
    Moskowitz
  6. Straus
    Straus
  7. Stubblefield
    Stubblefield
  8. Zelenetz
    Zelenetz
  9. Busam
    Busam
  10. Feldstein
    Feldstein

Groups

  1. Department of Medicine (4)
  2. Hematologic Malignancies, Division of (4)
  3. Nursing (4)
  4. Biostatistics Service (2)
  5. Center for Hematologic Malignancies (2)
  6. Epidemiology and Biostatistics (2)
  7. Lymphoma (2)
  8. Center for Pancreatic Cancer Research (1)
  9. Genitourinary Oncology Service (1)
  10. Melanoma Disease Management Team (1)
  1. "nonhodgkin lymphoma"
  2. "Barbara Macgregor-Cortelli"
Formats
  1. Journal Article (4)
Groups
  1. Department of Medicine (4)
  2. Hematologic Malignancies, Division of (4)
  3. Nursing (4)
  4. Biostatistics Service (2)
  5. Center for Hematologic Malignancies (2)
  6. Epidemiology and Biostatistics (2)

More Groups

People
  1. Barbara Macgregor-Cortelli (4)
  2. Owen O'connor (4)
  3. Jamie Muzzy (3)
  4. Andrew Zelenetz (2)
  5. Craig Moskowitz (2)
  6. David Straus (2)

More People

Years
  1. 2006 (2)
  2. 2005 (1)
  3. 2004 (1)
Publications
  1. British Journal of Haematology (1)
  2. Clinical Oncology (1)
  3. Journal of Clinical Oncology (1)
  4. Journal of the National Comprehensive Cancer Network (1)
Publishers
  1. American Society of Clinical Oncology (1)
  2. Elsevier Science, Inc. (1)
  3. Harborside Press (1)
  4. John Wiley & Sons (1)

Results (4)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib
    Journal Article

    Stubblefield, M. D.; Slovin, S.; Macgregor-Cortelli, B.; Muzzy, J.; Scher, H.; Wright, J.; Esseltine, D.; Schenkein, D.; O'Connor, O. A.
    Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: A possible surrogate marker of response?
    Journal Article

    Gerecitano, J.; Goy, A.; Wright, J.; Macgregor-Cortelli, B.; Neylon, E.; Gonen, M.; Esseltine, D.; Boral, A.; Schenkein, D.; Busam, K.; more...
    British Journal of Haematology (2006)

    Fulltext@MSK | Save
  • Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
    Journal Article

    O'Connor, O. A.; Wright, J.; Moskowitz, C.; Muzzy, J.; Macgregor-Cortelli, B.; Stubblefield, M.; Straus, D.; Portlock, C.; Hamlin, P.; Choi, E.; more...
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II
    Journal Article

    O'connor, O.; Wright, J.; Moskowitz, C. H.; Muzzy, J.; Macgregor-Cortelli, B.; Hamlin, P.; Straus, D.; Trehu, E.; Schenkein, D. P.; Zelenetz, A. D.
    Journal of the National Comprehensive Cancer Network (2004)

    Fulltext@MSK | Save